• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Global pharma industry outlook changes to stable

Report: Global pharma industry outlook changes to stable

March 7, 2016
CenterWatch Staff

Lower pricing flexibility, the stronger U.S. dollar and slower adoption of some new products will dampen earnings growth in the global pharmaceutical industry, said Moody's Investors Service. As a result, the rating agency has changed its outlook on the sector to stable from positive.

"We are changing our outlook for the global pharmaceutical industry to stable from positive because of a modest reduction in our expectations for the industry's earnings growth, said Michael Levesque, a Moody's senior vice president. "We now expect growth of 3% to 4% versus our previous expectation of 4% to 5%."

Moody's noted that pricing in the U.S. was one of the contributing factors to the outlook change. Owing to the continuing debate around high drug prices in the U.S., many manufacturers are taking more modest price increases than in the past.

Pricing remains a headwind in Europe and Japan, where greater generic drug use is encouraged. In addition, the stronger U.S. dollar will hurt large U.S.-based companies with overseas operations, but help non-U.S. drug manufacturers.

Moody's also notes that adoption rates for some products from large pharmaceutical companies have been slower than the agency expected. However, growth remains strong for cancer drugs, especially those in the immuno-oncology category like Bristol-Myers Squibb's (A2 stable) Opdivo and Merck & Co.'s (A1 stable) Keytruda.

Patent expirations for blockbuster drugs will remain modest through late 2017, with the exception of AstraZeneca's (A3 stable) Crestor, whose patent will expire in the U.S. in 2016 and in the EU in 2017.

"Cost savings from acquisitions will also help industry earnings growth," said Levesque."Pharmaceutical companies will remain active in the M&A market as they try to cut costs, achieve greater scale and diversification and acquire pipeline drugs with high potential."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing